이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Avacincaptad Pegol(Izervay™)이 지리적 위축이 있는 사람들의 임상 실습에 어떻게 사용되는지 알아보기 위한 연구

2026년 10월 26일 업데이트: Astellas Pharma Global Development, Inc.

연령 관련 황반변성에 이차적으로 발생하는 지도형 위축 환자의 일상적인 임상 실습에서 Avacincaptad Pegol(ACP/IZERVAY™)의 치료 패턴 및 안전성을 평가하기 위한 비중재, 관찰 연구

This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vision.

Avacincaptad pegol can help slow down the worsening or progression of geographic atrophy. Avacincaptad pegol is a treatment approved in the US to treat geographic atrophy.

This study is about collecting information on how people with geographic atrophy are treated in routine clinical practice. This includes recording any medical problems from avacincaptad pegol. This is known as an observational study. Information will be collected from the peoples' medical records during and after treatment. The people in this study will have geographic atrophy in 1 or both eyes and they and their doctor have decided they will be treated with avacincaptad pegol. The individual's doctor decides on treatment, not the study sponsor (Astellas).

People that want to take part in the study will have eye examinations that they would usually have as part of their routine care. People will also be asked to complete surveys about their eye health. These surveys will occur when treatment starts and then every 6 months for the first 2 years. After 2 years the surveys will happen once a year. The people on the study can take part if their doctor provides treatment with avacincaptad pegol and they want to continue with the study. The people on the study can take part for around 5 years.

연구 개요

상태

모집하지 않고 적극적으로

연구 유형

관찰

등록 (실제)

488

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Arizona
      • Phoenix, Arizona, 미국, 85053
        • Retinal Consultants of AZ
      • Scottsdale, Arizona, 미국, 85255
        • Retina Macula Institute of Arizona
    • California
      • Laguna Hills, California, 미국, 92653
        • Harvard Eye Associates
      • Orange, California, 미국, 92868
        • University of California Irvine Medical Center
      • Redlands, California, 미국, 92374
        • Retina Consultants of Southern CA
      • Sacramento, California, 미국, 95825
        • Retinal Consultants Medical Group Inc
      • Torrance, California, 미국, 90503
        • Retina Macula Institute
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • Rocky Mountain Lions Eye Institute
      • Colorado Springs, Colorado, 미국, 80909
        • Retina Consultants of Southern Colorado
      • Lakewood, Colorado, 미국, 80228
        • Colorado Retina Associates, PLLC
    • Connecticut
      • Greenwich, Connecticut, 미국, 05830
        • Coastal Eye Surgeons
    • Florida
      • Bonita Springs, Florida, 미국, 34134
        • Advanced Retina Institute
      • Coral Gables, Florida, 미국, 33146
        • University of Miami
      • Palm Beach Gardens, Florida, 미국, 33410
        • Retina Care Specialists
      • Tampa, Florida, 미국, 33606
        • Eye Physicians of Pinellas PA dba Eye Institute of West Florida
      • Wesley Chapel, Florida, 미국, 33544
        • Retina Specialists of Tampa
    • Georgia
      • Augusta, Georgia, 미국, 30909
        • Southeast Retina Center, P.C.
    • Illinois
      • Oak Forest, Illinois, 미국, 60452
        • University Retina and Macula Associates, P.C.
      • Oak Park, Illinois, 미국, 60304
        • Illinois Retina Associates
      • Peoria, Illinois, 미국, 61615
        • Illinois Eye Center
    • Iowa
      • West Des Moines, Iowa, 미국, 50266
        • Wolfe Eye Clinic
    • Maryland
      • Hagerstown, Maryland, 미국, 21740
        • Cumberland Valley Retina Consultants,P.C.
    • Michigan
      • Grand Blanc, Michigan, 미국, 48439
        • Retina Associates of Michigan
    • Minnesota
      • Saint Louis Park, Minnesota, 미국, 55416
        • Retina Consultants of Minnesota PLLC
    • Mississippi
      • Madison, Mississippi, 미국, 39110
        • Mississippi Retina Associates
      • Olive Branch, Mississippi, 미국, 38654
        • Brown Family Retina PLLC
      • Southaven, Mississippi, 미국, 38671
        • Deep Blue Retina Clinical Research
    • Nevada
      • Reno, Nevada, 미국, 89502
        • Sierra Eye Associates
    • New Jersey
      • Dover, New Jersey, 미국, 07801
        • Eye Associates of North Jersey PA
      • Edison, New Jersey, 미국, 08820
        • NJ Retina
      • Lakewood, New Jersey, 미국, 08701
        • NJ Retina
      • Toms River, New Jersey, 미국, 08755
        • NJ Retina
    • New York
      • Brentwood, New York, 미국, 11717
        • SightMD
      • Liverpool, New York, 미국, 13088
        • Retina-Vitreous Surgeons of Central NY
      • Massapequa, New York, 미국, 11758
        • NY Retina Ophthalmology PLLC
      • New York, New York, 미국, 10075
        • Retina Associates of New York
      • Scarsdale, New York, 미국, 10583
        • Long Island Vitreoretinal Consultants
      • Shirley, New York, 미국, 11967
        • Vitreoretinal Consultants
    • North Carolina
      • Wake Forest, North Carolina, 미국, 27587
        • North Carolina Retina Associates
    • Ohio
      • Columbus, Ohio, 미국, 43221
        • The Ohio State University
      • Dayton, Ohio, 미국, 45459
        • CEI Physicians PSC, LLC dba
    • Oregon
      • Eugene, Oregon, 미국, 97401
        • Verum Research, LLC
    • Pennsylvania
      • Erie, Pennsylvania, 미국, 16507
        • Erie Retina Research
    • Tennessee
      • Knoxville, Tennessee, 미국, 37920
        • Southeastern Retina Associates, P.C.
      • Knoxville, Tennessee, 미국, 37923
        • Southeastern Retina Associates, P.C.
      • Memphis, Tennessee, 미국, 38119
        • Mid South Retina Associates
      • Nashville, Tennessee, 미국, 37203
        • Tennessee Retina, PC
    • Texas
      • Abilene, Texas, 미국, 79606
        • Retina Research Institute of Texas
      • Dallas, Texas, 미국, 75243
        • Retina of North Texas
      • McAllen, Texas, 미국, 78503
        • Valley Retina Institute
      • San Antonio, Texas, 미국, 78240
        • Medical Center Ophthalmology Associates
      • San Antonio, Texas, 미국, 78240
        • Retina Associates Of South Texas, Pa
    • Utah
      • Murray, Utah, 미국, 84107
        • Retina Associates of Utah, P.C.
      • Salt Lake City, Utah, 미국, 84120
        • Salt Lake Retina
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • The Retina Group of Washington
      • Lynchburg, Virginia, 미국, 24502
        • Piedmont Eye Center, Inc.
      • Warrenton, Virginia, 미국, 20186
        • Virginia Retina Center
    • Wisconsin
      • Milwaukee, Wisconsin, 미국, 53226
        • Retina & Vitreous Consultants of Wisconsin

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이
  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Participants from both academic and non-academic sites, urban and rural across the US to ensure a heterogenous population that is representative of the US GA secondary to AMD population and reflective of real-world practice patterns.

설명

Inclusion Criteria:

  • Patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in 1 or both eyes
  • Patient with a decision to treat with intravitreal avacincaptad pegol (ACP) prior to enrollment
  • Patient willingness to complete the patient reported outcome (PRO).

Exclusion Criteria:

  • Patients who have any contraindication or are not eligible for treatment with ACP, including the following:

    • Active ocular or peri-ocular infection in either eye
    • Active, suspected intraocular inflammation in either eye
    • Hypersensitive to ACP or to any ingredient in the formulation
  • Patients currently participating in an investigational program with interventions outside of routine clinical practice.

  • Patients who have received ACP in the eye being considered for enrollment. Note: Patients who have received or are receiving ACP in the fellow eye at baseline are eligible to be included in the study.

  • Patients who have received any intravitreal complement inhibitor other than ACP in either eye. Note: Patients who have received an intravitreal complement inhibitor other than ACP in either eye and have completed the 90-day washout period are eligible to be included in the study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Izervay

Patients with geographic atrophy (GA) secondary to AMD who have made decision to begin treatment with Izervay

intravitreal injection

다른 이름들:
  • 아이저베이™

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of ACP injections
기간: Up to 61 Months

The number of ACP injections.

Up to 61 Months
Duration of treatment
기간: Up to 61 Months

The duration of treatment will be calculated as the difference between the date of the last injection and the date of the first injection plus 31 days (as the next injection would be expected at least 30 days after the last one).

Up to 61 Months
Annual frequency of ACP injection
기간: Up to 61 Months

The annual frequency of ACP injections will be calculated as the total number of injections divided by the treatment duration in years.

Up to 61 Months
Reasons for discontinuation of treatment with ACP
기간: Up to 61 Months

The reasons for discontinuation of treatment with ACP will be recorded.

Up to 61 Months
Duration of the treatment interval
기간: Up to 61 Months

The treatment interval is defined as mean number of days between injections, if a study eye receives more than 1 injection.

Up to 61 Months
Site characteristics
기간: Day 1

Characteristics of interest will be recorded including the type of setting (e.g., public/private facility, rural/urban).

Day 1
Characteristics of patients with geographic atrophy (GA) secondary to AMD beginning treatment with Izervay
기간: Day 1

Characteristics of interest will be recorded.

Day 1

2차 결과 측정

결과 측정
측정값 설명
기간
Number of participants with Adverse Events (AEs)
기간: Up to 61 Months

An AE is defined as any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment.

An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal (investigational) product.

Up to 61 Months
Number of participants with Serious Adverse Events (SAEs)
기간: Up to 61 Months

An SAE is defined as an AE that results in death, is life-threatening, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or other medically important events.

Up to 61 Months
Number of participants with Treatment Emergent Adverse Events (TEAEs)
기간: Up to 61 Months

TEAE is defined an AE observed after starting administration of the study drug and will continue until 30 days after the last administration or until last study visit, whichever is sooner.

Up to 61 Months
Number of participants with Adverse Event of Special Interest (AESI)
기간: Up to 61 Months

AESIs are defined as the following AEs:

  • Endophthalmitis
  • choroidal neovascularization (CNV)
  • Intraocular inflammation (including retinal vasculitis)
  • Increased intraocular pressure (IOP) ≥ 30 mmHg at 30 minutes post injection deemed clinically significant by the investigator
  • Elevation of IOP post injection requiring surgical/procedural intervention
  • Ischemic optic neuropathy
Up to 61 Months
Number of Participants maintaining vision
기간: Up to 61 Months

Maintaining vision is defined as not losing ≥ 15 letters on Early Treatment Diabetic Retinopathy Study (ETDRS) chart.

Up to 61 Months
Time to vision loss using various thresholds
기간: Up to 61 Months

Time to vision loss is defined as the difference between the date when vision loss was reported for the first time and the start date of treatment.

Up to 61 Months
Time to thresholds associated with ability to drive
기간: Up to 61 Months

Time to thresholds associated with the ability to drive will be based on visual acuity data captured as per standard of care.

Up to 61 Months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Medical Director, Astellas Pharma Global Development, Inc.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 1월 22일

기본 완료 (추정된)

2030년 10월 31일

연구 완료 (추정된)

2030년 10월 31일

연구 등록 날짜

최초 제출

2024년 12월 16일

QC 기준을 충족하는 최초 제출

2025년 1월 13일

처음 게시됨 (실제)

2025년 1월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 27일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 26일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다